Chairperson’s Perspective: Evidence-Informed Clinical Decision-Making in HER2-Overexpressed and TROP2-Targeted NSCLC
Benjamin Levy, MD
Beyond the Joint: Cross-Specialty Solutions for Advancing TGCT Patient Care
A.J. Gelderblom, MD, PhD
Michiel van de Sande, MD, PhD
Chelsea Cole, MD
Patient Perspective: Navigating TGCT Treatment—Surgery vs Systemic Therapy
Applying the Evidence: TGCT Treatment Insights for Sports Medicine Physicians
Surgical Crossroads: Practical Considerations for Optimizing Treatment in TGCT
The Tumor That’s Not So Tiny: Understanding the Impact of TGCT
Clinical Evidence in Focus: Interpreting Data on Systemic Therapy Targeting CSF1R
Unlocking the CSF1R Code: Targeted Pathways and Tailored Choices
Safety of CDK4/6 Inhibitors: Anticipation, Prevention, and Management of Adverse Events
Giuseppe Curigliano, MD, PhD
Beyond Fulvestrant: Oral SERDs Redefining ER Targeting
Komal Jhaveri, MD, FACP
Breaking Down the Benchmarks: Pivotal Data on First-Line CDK4/6 Inhibitors
The Future of Oral SERDs: Combination Strategies
Spotlight on Latin America: Closing the Gap
Cynthia Villarreal-Garza, MD, DSc
Safety and Tolerability of CDH6-Directed Antibody-Drug Conjugates
Kathleen Moore, MD, MS
MOA: CDH6-Targeted Antibody-Drug Conjugates
Navigating the Therapeutic Landscape of Platinum-Resistant Ovarian Cancer
Joyce F. Liu, MD, MPH
Loading...
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We're glad to see you're enjoying Global Oncology Academy… but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.